BR0312691A - Métodos para converter uma cepa hospedeira em uma cepa recombinante, para gerar uma cepa recombinante contendo agrupamento biossintéticos, para produzir um análogo de um ligando de fbkp, para construir uma coleção de colÈnias de cepas recombinantes e para preparar uma coleção combinatorial de ligando de fkbp, coleção de análogos de ligando fbkp, cepa recombinante, método para gerar análogos de ligandos de fbkp, composto, e, uso do mesmo - Google Patents
Métodos para converter uma cepa hospedeira em uma cepa recombinante, para gerar uma cepa recombinante contendo agrupamento biossintéticos, para produzir um análogo de um ligando de fbkp, para construir uma coleção de colÈnias de cepas recombinantes e para preparar uma coleção combinatorial de ligando de fkbp, coleção de análogos de ligando fbkp, cepa recombinante, método para gerar análogos de ligandos de fbkp, composto, e, uso do mesmoInfo
- Publication number
- BR0312691A BR0312691A BR0312691-9A BR0312691A BR0312691A BR 0312691 A BR0312691 A BR 0312691A BR 0312691 A BR0312691 A BR 0312691A BR 0312691 A BR0312691 A BR 0312691A
- Authority
- BR
- Brazil
- Prior art keywords
- ligand
- fbkp
- collection
- recombinant
- strain
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 6
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 230000001851 biosynthetic effect Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 229930001119 polyketide Natural products 0.000 abstract 2
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 abstract 1
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229930014626 natural product Natural products 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000003881 polyketide derivatives Chemical class 0.000 abstract 1
- 125000000830 polyketide group Chemical group 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
- 229960002930 sirolimus Drugs 0.000 abstract 1
- 230000009466 transformation Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/76—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Actinomyces; for Streptomyces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0216509A GB0216509D0 (en) | 2002-07-16 | 2002-07-16 | Production of polyketides and other natural products |
| GB0224922A GB0224922D0 (en) | 2002-10-25 | 2002-10-25 | Production of polyketides and other natural products |
| PCT/GB2003/003230 WO2004007709A2 (en) | 2002-07-16 | 2003-07-16 | Production of polyketides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0312691A true BR0312691A (pt) | 2005-05-10 |
Family
ID=30117119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0312691-9A BR0312691A (pt) | 2002-07-16 | 2003-07-16 | Métodos para converter uma cepa hospedeira em uma cepa recombinante, para gerar uma cepa recombinante contendo agrupamento biossintéticos, para produzir um análogo de um ligando de fbkp, para construir uma coleção de colÈnias de cepas recombinantes e para preparar uma coleção combinatorial de ligando de fkbp, coleção de análogos de ligando fbkp, cepa recombinante, método para gerar análogos de ligandos de fbkp, composto, e, uso do mesmo |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US7300942B2 (enExample) |
| EP (5) | EP2277898A3 (enExample) |
| JP (5) | JP2005532809A (enExample) |
| CN (1) | CN100569944C (enExample) |
| AT (1) | ATE370161T1 (enExample) |
| AU (1) | AU2003246965B2 (enExample) |
| BR (1) | BR0312691A (enExample) |
| CA (1) | CA2492153C (enExample) |
| CY (1) | CY1107764T1 (enExample) |
| DE (1) | DE60315723T2 (enExample) |
| DK (1) | DK1589031T3 (enExample) |
| ES (2) | ES2544624T3 (enExample) |
| MX (1) | MXPA05000139A (enExample) |
| PT (1) | PT1589031E (enExample) |
| WO (1) | WO2004007709A2 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2544624T3 (es) * | 2002-07-16 | 2015-09-02 | Buck Institute For Research On Aging | Producción de policétidos |
| AU2004274026A1 (en) | 2003-09-18 | 2005-03-31 | Macusight, Inc. | Transscleral delivery |
| BRPI0510277A (pt) * | 2004-04-27 | 2007-10-30 | Wyeth Corp | método para marcar especificamente uma rapamicina, rapamicina especificamente marcada, composição, e, kit |
| JP2008501342A (ja) | 2004-06-03 | 2008-01-24 | ワイス | 複合ポリケチドを生成するための生合成遺伝子クラスター |
| GB0417852D0 (en) | 2004-08-11 | 2004-09-15 | Biotica Tech Ltd | Production of polyketides and other natural products |
| MX2007007409A (es) | 2004-12-20 | 2007-07-12 | Wyeth Corp | Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos. |
| RU2394036C2 (ru) | 2004-12-20 | 2010-07-10 | Вайет | Аналоги рапамицина и их применение при лечении неврологических, пролиферативных и воспалительных заболеваний |
| CA2597590A1 (en) | 2005-02-09 | 2006-08-17 | Macusight, Inc. | Formulations for ocular treatment |
| US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| GB0504995D0 (en) | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Use of a compound |
| AU2006221774A1 (en) * | 2005-03-11 | 2006-09-14 | Biotica Technology Limited | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
| BRPI0608726A2 (pt) * | 2005-03-11 | 2011-03-15 | Biotica Tech Ltd | uso de um análogo de 39-desmetoxirapamicina ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica |
| GB0504994D0 (en) * | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
| WO2007092620A2 (en) | 2006-02-09 | 2007-08-16 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
| US8222271B2 (en) | 2006-03-23 | 2012-07-17 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
| GB0609962D0 (en) * | 2006-05-19 | 2006-06-28 | Biotica Tech Ltd | Novel compounds |
| GB0609963D0 (en) | 2006-05-19 | 2006-06-28 | Biotica Tech Ltd | Novel compounds |
| KR100750810B1 (ko) | 2006-08-07 | 2007-08-22 | 동국제약 주식회사 | 스트렙토마이세스 히그로스코피쿠스 ａｔｃｃ １４８９１변이주 및 이를 이용한 타크로리무스 생산 방법 |
| DK2142638T3 (en) * | 2007-04-02 | 2016-12-12 | Newsouth Innovations Pty Ltd | Process for the production of secondary metabolites |
| TW200845960A (en) * | 2007-04-05 | 2008-12-01 | Wyeth Corp | Wortmannin-rapalog conjugate and uses thereof |
| US20080287675A1 (en) * | 2007-05-18 | 2008-11-20 | Abbott Laboratories | Cascade system |
| EP2245165A4 (en) * | 2008-01-11 | 2011-06-01 | Massachusetts Eye & Ear Infirm | TRANSGENIC CONDITIONAL STOP DIMERICABLE CASPASE ANIMALS |
| US8962329B2 (en) | 2008-09-24 | 2015-02-24 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Gene cluster |
| GB0904540D0 (en) | 2009-03-17 | 2009-04-29 | Biotica Tech Ltd | Novel compounds and methods for their production |
| GB0914589D0 (en) | 2009-08-20 | 2009-09-30 | Biotica Tech Ltd | Novel compounds and methods for their production |
| GB0917816D0 (en) | 2009-10-12 | 2009-11-25 | Biotica Tech Ltd | Novel compounds and methods for their production |
| GB0917817D0 (en) | 2009-10-12 | 2009-11-25 | Biotica Tech Ltd | Novel compounds and methods for their production |
| CA2820800A1 (en) | 2010-12-08 | 2012-06-14 | Oslo University Hospital Hf | Triazole derivatives as wnt signaling pathway inhibitors |
| EP2589383A1 (en) | 2011-11-06 | 2013-05-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin | FKBP subtype-specific rapamycin analogue for use in treatment of diseases |
| GB201122305D0 (en) * | 2011-12-23 | 2012-02-01 | Biotica Tech Ltd | Novel compound |
| CN103212064B (zh) * | 2012-01-19 | 2016-02-17 | 中国科学院上海巴斯德研究所 | 磷酸化途径相关因子在调控调节性t细胞功能中的应用 |
| KR101331491B1 (ko) | 2012-03-21 | 2013-11-20 | 이화여자대학교 산학협력단 | 증가된 라파마이신 생성능을 갖는 신규 미생물 균주 |
| GB201312318D0 (en) | 2013-07-09 | 2013-08-21 | Isomerase Therapeutics Ltd | Novel methods and compounds |
| WO2017040341A1 (en) * | 2015-08-28 | 2017-03-09 | Buck Institute For Research On Aging | RAPAMYCIN ANALOGS SHOWING IMPROVED mTORC1 SPECIFICITY |
| JP2020507632A (ja) | 2017-02-10 | 2020-03-12 | マウント タム セラピューティクス, インコーポレイテッドMount Tam Therapeutics, Inc. | ラパマイシン類似体 |
| US20210030726A1 (en) * | 2018-02-09 | 2021-02-04 | Torcept Therapeutics, Inc. | Rapamycin analog for prevention and/or treatment of neurodegnerative conditions |
| WO2019157363A2 (en) * | 2018-02-09 | 2019-08-15 | Mount Tam Therapeutics, Inc. | Rapamycin analog for prevention and/or treatment of cancer |
| EA202191983A1 (ru) | 2019-01-22 | 2021-12-01 | Аеовиан Фармасьютикалз, Инк. | МОДУЛЯТОРЫ mTORC И ИХ ПРИМЕНЕНИЕ |
| CN115125179B (zh) * | 2021-03-26 | 2023-10-27 | 上海医药工业研究院 | 产雷帕霉素的基因工程菌及其应用 |
| EP4359417A2 (en) * | 2021-06-25 | 2024-05-01 | Apertor Pharmaceuticals, Inc. | Small molecule compounds |
| US20240350463A1 (en) * | 2021-06-25 | 2024-10-24 | Apertor Pharmaceuticals, Inc. | Small molecule compounds |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US3993749A (en) | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
| SE416705B (sv) | 1978-02-27 | 1981-02-02 | Torsten & Andersson Kaj | Anordning for utskjutning av bollar |
| GB2165090A (en) | 1984-09-26 | 1986-04-03 | Philips Electronic Associated | Improving the field distribution in high voltage semiconductor devices |
| JPS6453991A (en) | 1987-08-25 | 1989-03-01 | Mitsubishi Electric Corp | Magazine-cum-reel |
| US5109112A (en) | 1989-01-19 | 1992-04-28 | Merck & Co., Inc. | FK-506 cytosolic binding protein |
| US5023262A (en) | 1990-08-14 | 1991-06-11 | American Home Products Corporation | Hydrogenated rapamycin derivatives |
| US5221670A (en) | 1990-09-19 | 1993-06-22 | American Home Products Corporation | Rapamycin esters |
| US5143918A (en) * | 1990-10-11 | 1992-09-01 | Merck & Co., Inc. | Halomacrolides and derivatives having immunosuppressive activity |
| WO1993013663A1 (en) | 1992-01-17 | 1993-07-22 | Abbott Laboratories | Method of directing biosynthesis of specific polyketides |
| US5091389A (en) * | 1991-04-23 | 1992-02-25 | Merck & Co., Inc. | Lipophilic macrolide useful as an immunosuppressant |
| US5093338A (en) | 1991-04-23 | 1992-03-03 | Merck & Co., Inc. | Lipophilic macrolide useful as an immunosuppressant |
| US5138051A (en) | 1991-08-07 | 1992-08-11 | American Home Products Corporation | Rapamycin analogs as immunosuppressants and antifungals |
| WO1992021341A1 (en) | 1991-05-31 | 1992-12-10 | Pfizer Inc. | Use of rapamycin prodrugs as immunosuppressant agents |
| US5763590A (en) | 1991-10-11 | 1998-06-09 | Vertex Pharmaceuticals, Inc. | Isolation of an Mr 52,000 FK506 binding protein and molecular cloning of a corresponding human cDNA |
| GB9125660D0 (en) | 1991-12-03 | 1992-01-29 | Smithkline Beecham Plc | Novel compound |
| US5498597A (en) | 1992-01-17 | 1996-03-12 | Dana-Farber Cancer Institute, Inc. | FKBP-13, an FK506-binding immunophilin |
| JP3140228B2 (ja) * | 1992-02-17 | 2001-03-05 | ファイザー製薬株式会社 | 新規な大環状ラクトンおよびその生産菌 |
| ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
| GB9302569D0 (en) | 1993-02-10 | 1993-03-24 | Smithkline Beecham Plc | Novel compound |
| US5354845A (en) | 1993-04-21 | 1994-10-11 | Children's Research Institute | FK-506 and rapamycin specific binding immunophilin |
| GB9315914D0 (en) * | 1993-07-31 | 1993-09-15 | Smithkline Beecham Plc | Novel compound |
| US5387680A (en) * | 1993-08-10 | 1995-02-07 | American Home Products Corporation | C-22 ring stabilized rapamycin derivatives |
| US5373014A (en) | 1993-10-08 | 1994-12-13 | American Home Products Corporation | Rapamycin oximes |
| US5378836A (en) | 1993-10-08 | 1995-01-03 | American Home Products Corporation | Rapamycin oximes and hydrazones |
| US5391730A (en) | 1993-10-08 | 1995-02-21 | American Home Products Corporation | Phosphorylcarbamates of rapamycin and oxime derivatives thereof |
| UA41884C2 (uk) * | 1993-11-05 | 2001-10-15 | Амерікан Хоум Продактс Корпорейшн | Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів |
| EP0729471A1 (en) * | 1993-11-19 | 1996-09-04 | Abbott Laboratories | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
| NZ277498A (en) | 1993-12-17 | 1998-03-25 | Novartis Ag | Rapamycin derivatives |
| US5457182A (en) | 1994-02-15 | 1995-10-10 | Merck & Co., Inc. | FK-506 cytosolic binding protein, FKBP12.6 |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| US5563145A (en) | 1994-12-07 | 1996-10-08 | American Home Products Corporation | Rapamycin 42-oximes and hydroxylamines |
| KR100400620B1 (ko) | 1995-06-09 | 2004-02-18 | 노파르티스 아게 | 라파마이신유도체 |
| EP0836649B1 (en) | 1995-07-06 | 2004-12-29 | The Leland Stanford Junior University | Cell-free synthesis of polyketides |
| US5780462A (en) | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
| GB9710962D0 (en) | 1997-05-28 | 1997-07-23 | Univ Cambridge Tech | Polyketides and their synthesis |
| WO1998001546A2 (en) | 1996-07-05 | 1998-01-15 | Biotica Technology Limited | Polyketides and their synthesis |
| US6239124B1 (en) | 1996-07-30 | 2001-05-29 | Novartis Ag | Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin |
| WO1998009972A1 (en) * | 1996-09-09 | 1998-03-12 | American Home Products Corporation | Rapamycin derivatives with unnatural stereochemistries |
| JP2001518784A (ja) * | 1997-04-09 | 2001-10-16 | アイソテクニカ，インコーポレイテッド | ラパマイシンの特異的部位に対する抗体の産生方法 |
| US6015815A (en) | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
| AU4549999A (en) * | 1998-06-08 | 1999-12-30 | Advanced Medicine, Inc. | Novel polyene macrolide compounds and uses |
| GB9814006D0 (en) | 1998-06-29 | 1998-08-26 | Biotica Tech Ltd | Polyketides and their synthesis |
| GB9814622D0 (en) | 1998-07-06 | 1998-09-02 | Biotica Tech Ltd | Polyketides,their preparation,and materials for use therein |
| US6150513A (en) | 1998-09-16 | 2000-11-21 | Kosan Biosciences, Inc. | Polyketide synthase enzymes and recombinant DNA constructs therefor |
| US6503737B1 (en) * | 1998-10-02 | 2003-01-07 | Kosan Biosciences, Inc. | Isolated nucleic acids relating to the fkbA gene within the FK-520 polyketide synthase gene cluster |
| SE516023C2 (sv) | 1999-06-24 | 2001-11-12 | Abb Ab | Industrirobot innefattande en växellådskonfiguration samt förfarande i en industrirobot |
| EP1200078A4 (en) | 1999-07-09 | 2004-06-30 | Univ Oregon Health & Science | COMPOSITIONS AND METHODS ACTIVATING NERVOUS REGENERATION |
| US6569867B2 (en) | 1999-10-01 | 2003-05-27 | Kosan Biosciences, Inc. | Polyketide derivatives |
| DE60033965T2 (de) * | 1999-10-29 | 2008-01-10 | Kosan Biosciences, Inc., Hayward | Rapamycin analoge |
| JP5037771B2 (ja) | 2000-04-13 | 2012-10-03 | バイオチカ テクノロジー リミテッド | グリコシル化されたハイブリッド産物およびその産生方法と利用 |
| WO2001087884A2 (en) * | 2000-05-17 | 2001-11-22 | Kosan Biosciences, Inc. | Polyketide derivatives |
| GB0019986D0 (en) | 2000-08-14 | 2000-10-04 | Biotica Tech Ltd | Polyketides and their synthesis |
| US6534693B2 (en) * | 2000-11-06 | 2003-03-18 | Afmedica, Inc. | Surgically implanted devices having reduced scar tissue formation |
| GB0128680D0 (en) | 2001-11-29 | 2002-01-23 | Biotica Tech Ltd | Hybrid glycosylated products and their production and use |
| JP4547911B2 (ja) * | 2002-02-01 | 2010-09-22 | アリアド・ファーマシューティカルズ・インコーポレイテッド | リン含有化合物およびその用途 |
| CA2621517C (en) | 2002-07-16 | 2014-03-25 | Biotica Technology Limited | Production of polyketides fkbp-ligand analogues |
| ES2544624T3 (es) | 2002-07-16 | 2015-09-02 | Buck Institute For Research On Aging | Producción de policétidos |
| AU2007237187B2 (en) | 2002-07-16 | 2010-08-05 | Biotica Technology Limited | Production of polyketides |
| GB0216509D0 (en) | 2002-07-16 | 2002-08-28 | Biotica Tech Ltd | Production of polyketides and other natural products |
-
2003
- 2003-07-16 ES ES03764029.9T patent/ES2544624T3/es not_active Expired - Lifetime
- 2003-07-16 CN CNB038169169A patent/CN100569944C/zh not_active Expired - Fee Related
- 2003-07-16 EP EP10179385A patent/EP2277898A3/en not_active Withdrawn
- 2003-07-16 MX MXPA05000139A patent/MXPA05000139A/es active IP Right Grant
- 2003-07-16 CA CA2492153A patent/CA2492153C/en not_active Expired - Fee Related
- 2003-07-16 EP EP05075774A patent/EP1589031B1/en not_active Expired - Lifetime
- 2003-07-16 US US10/497,135 patent/US7300942B2/en not_active Expired - Lifetime
- 2003-07-16 EP EP05077470A patent/EP1655372A3/en not_active Withdrawn
- 2003-07-16 PT PT05075774T patent/PT1589031E/pt unknown
- 2003-07-16 AT AT05075774T patent/ATE370161T1/de active
- 2003-07-16 DK DK05075774T patent/DK1589031T3/da active
- 2003-07-16 WO PCT/GB2003/003230 patent/WO2004007709A2/en not_active Ceased
- 2003-07-16 JP JP2004520912A patent/JP2005532809A/ja active Pending
- 2003-07-16 ES ES05075774T patent/ES2296063T3/es not_active Expired - Lifetime
- 2003-07-16 EP EP08075113A patent/EP1967520A2/en not_active Withdrawn
- 2003-07-16 BR BR0312691-9A patent/BR0312691A/pt not_active IP Right Cessation
- 2003-07-16 DE DE60315723T patent/DE60315723T2/de not_active Expired - Lifetime
- 2003-07-16 AU AU2003246965A patent/AU2003246965B2/en not_active Ceased
- 2003-07-16 EP EP03764029.9A patent/EP1521828B1/en not_active Expired - Lifetime
-
2005
- 2005-11-08 US US11/269,215 patent/US20060078980A1/en not_active Abandoned
-
2007
- 2007-07-16 US US11/778,264 patent/US7390895B2/en not_active Expired - Lifetime
- 2007-07-16 US US11/778,319 patent/US7645768B2/en not_active Expired - Fee Related
- 2007-10-15 CY CY20071101328T patent/CY1107764T1/el unknown
- 2007-10-31 US US11/931,474 patent/US20080287482A1/en not_active Abandoned
-
2008
- 2008-02-07 JP JP2008028178A patent/JP2008200039A/ja not_active Ceased
- 2008-02-07 JP JP2008028177A patent/JP4751899B2/ja not_active Expired - Fee Related
-
2009
- 2009-11-09 JP JP2009255660A patent/JP2010075187A/ja not_active Withdrawn
-
2011
- 2011-03-11 US US13/046,304 patent/US9040259B2/en not_active Expired - Lifetime
-
2014
- 2014-04-09 JP JP2014080591A patent/JP2014176384A/ja active Pending
-
2015
- 2015-03-02 US US14/635,979 patent/US9605001B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0312691A (pt) | Métodos para converter uma cepa hospedeira em uma cepa recombinante, para gerar uma cepa recombinante contendo agrupamento biossintéticos, para produzir um análogo de um ligando de fbkp, para construir uma coleção de colÈnias de cepas recombinantes e para preparar uma coleção combinatorial de ligando de fkbp, coleção de análogos de ligando fbkp, cepa recombinante, método para gerar análogos de ligandos de fbkp, composto, e, uso do mesmo | |
| Dinglasan et al. | Microbial secondary metabolites: advancements to accelerate discovery towards application | |
| Carrell et al. | Novel metabolic interactions and environmental conditions mediate the boreal peatmoss-cyanobacteria mutualism | |
| Xu et al. | Recent advances in the applications of promoter engineering for the optimization of metabolite biosynthesis | |
| Delmotte et al. | An integrated proteomics and transcriptomics reference data set provides new insights into the Bradyrhizobium japonicum bacteroid metabolism in soybean root nodules | |
| Zhang et al. | Unlocking the trove of metabolic treasures: activating silent biosynthetic gene clusters in bacteria and fungi | |
| Baunach et al. | Harnessing the potential: advances in cyanobacterial natural product research and biotechnology | |
| Keasling | Synthetic biology and the development of tools for metabolic engineering | |
| Christiansen et al. | Microcystin biosynthesis in Planktothrix: genes, evolution, and manipulation | |
| Ma et al. | Linaridin natural products | |
| Liao et al. | Unexpected extensive lysine acetylation in the trump-card antibiotic producer Streptomyces roseosporus revealed by proteome-wide profiling | |
| van Dolleweerd et al. | MIDAS: a modular DNA assembly system for synthetic biology | |
| Milne et al. | Accomplishments in genome‐scale in silico modeling for industrial and medical biotechnology | |
| King et al. | Accessing Nature’s diversity through metabolic engineering and synthetic biology | |
| Morishita et al. | Synthetic-biology-based discovery of a fungal macrolide from Macrophomina phaseolina | |
| Biarnes-Carrera et al. | Orthogonal regulatory circuits for Escherichia coli based on the γ-butyrolactone system of Streptomyces coelicolor | |
| Breitling et al. | Synthetic biology of natural products | |
| Pilpel | Noise in biological systems: pros, cons, and mechanisms of control | |
| Kuzmenko et al. | Protein biosynthesis in mitochondria | |
| Zhang et al. | Synthetic biology of cyanobacteria | |
| Kai et al. | An acyl-SAM analog as an affinity ligand for identifying quorum sensing signal synthases | |
| Zhang et al. | Engineering a controllable targeted protein degradation system and a derived OR-GATE-type inducible gene expression system in Synechococcus elongatus PCC 7942 | |
| Breitling et al. | Synthetic biology approaches to actinomycete strain improvement | |
| Li et al. | Genetic mining of the “dark matter” in fungal natural products | |
| Yue et al. | Development of the static and dynamic gene expression regulation toolkit in Pseudomonas chlororaphis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |